﻿<?xml version="1.0" encoding="utf-8"?>
<Return returnVersion="2018v3.0" xmlns="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <ReturnHeader binaryAttachmentCnt="0">
    <ReturnTs>2019-10-15T09:45:17-07:00</ReturnTs>
    <TaxPeriodEndDt>2018-12-31</TaxPeriodEndDt>
    <ReturnTypeCd>990</ReturnTypeCd>
    <TaxPeriodBeginDt>2018-01-01</TaxPeriodBeginDt>
    <Filer>
      <EIN>264489946</EIN>
      <BusinessName>
        <BusinessNameLine1Txt>SAGE BIONETWORKS</BusinessNameLine1Txt>
      </BusinessName>
      <BusinessNameControlTxt>SAGE</BusinessNameControlTxt>
      <PhoneNum>2069288250</PhoneNum>
      <USAddress>
        <AddressLine1Txt>2901 Third Ave Ste 330</AddressLine1Txt>
        <CityNm>Seattle</CityNm>
        <StateAbbreviationCd>WA</StateAbbreviationCd>
        <ZIPCd>98121</ZIPCd>
      </USAddress>
    </Filer>
    <BusinessOfficerGrp>
      <PersonNm>Lara Mangravite</PersonNm>
      <PersonTitleTxt>President</PersonTitleTxt>
      <PhoneNum>2069288250</PhoneNum>
      <SignatureDt>2019-10-15</SignatureDt>
    </BusinessOfficerGrp>
    <FilingSecurityInformation>
      <IPAddress>
        <IPv4AddressTxt>207.109.76.122</IPv4AddressTxt>
      </IPAddress>
    </FilingSecurityInformation>
    <TaxYr>2018</TaxYr>
    <BuildTS>2019-02-21 02:37:17Z</BuildTS>
  </ReturnHeader>
  <ReturnData documentCnt="10">
    <IRS990 documentId="R000001" referenceDocumentId="R000009 R000010" softwareId="18007995" softwareVersionNum="v1.00">
      <PrincipalOfficerNm>Lara Mangravite</PrincipalOfficerNm>
      <USAddress>
        <AddressLine1Txt>2901 Third Ave</AddressLine1Txt>
        <AddressLine2Txt>Ste 330</AddressLine2Txt>
        <CityNm>Seattle</CityNm>
        <StateAbbreviationCd>WA</StateAbbreviationCd>
        <ZIPCd>98121</ZIPCd>
      </USAddress>
      <GrossReceiptsAmt>17958815</GrossReceiptsAmt>
      <GroupReturnForAffiliatesInd>0</GroupReturnForAffiliatesInd>
      <Organization501c3Ind>X</Organization501c3Ind>
      <WebsiteAddressTxt>www.sagebionetworks.org</WebsiteAddressTxt>
      <TypeOfOrganizationCorpInd>X</TypeOfOrganizationCorpInd>
      <FormationYr>2009</FormationYr>
      <LegalDomicileStateCd>WA</LegalDomicileStateCd>
      <ActivityOrMissionDesc>Sage Bionetworks is a strategic research organization with a mission to coordinate and link academic and commercial biomedical researchers, patients and citizens through a Commons that represents a new paradigm for genomics intellectual property, researcher cooperation and contributor evolved resources. This mission has several interdependent themes, including: conducting research on network models of disease; building the computational platform for the Commons; and activating public engagement.</ActivityOrMissionDesc>
      <VotingMembersGoverningBodyCnt>6</VotingMembersGoverningBodyCnt>
      <VotingMembersIndependentCnt>5</VotingMembersIndependentCnt>
      <TotalEmployeeCnt>71</TotalEmployeeCnt>
      <TotalVolunteersCnt>5</TotalVolunteersCnt>
      <TotalGrossUBIAmt>0</TotalGrossUBIAmt>
      <NetUnrelatedBusTxblIncmAmt>0</NetUnrelatedBusTxblIncmAmt>
      <PYContributionsGrantsAmt>7337401</PYContributionsGrantsAmt>
      <CYContributionsGrantsAmt>15555426</CYContributionsGrantsAmt>
      <PYProgramServiceRevenueAmt>3001123</PYProgramServiceRevenueAmt>
      <CYProgramServiceRevenueAmt>2402775</CYProgramServiceRevenueAmt>
      <PYInvestmentIncomeAmt>258</PYInvestmentIncomeAmt>
      <CYInvestmentIncomeAmt>614</CYInvestmentIncomeAmt>
      <PYOtherRevenueAmt>0</PYOtherRevenueAmt>
      <CYOtherRevenueAmt>0</CYOtherRevenueAmt>
      <PYTotalRevenueAmt>10338782</PYTotalRevenueAmt>
      <CYTotalRevenueAmt>17958815</CYTotalRevenueAmt>
      <PYGrantsAndSimilarPaidAmt>786047</PYGrantsAndSimilarPaidAmt>
      <CYGrantsAndSimilarPaidAmt>1886803</CYGrantsAndSimilarPaidAmt>
      <PYBenefitsPaidToMembersAmt>0</PYBenefitsPaidToMembersAmt>
      <CYBenefitsPaidToMembersAmt>0</CYBenefitsPaidToMembersAmt>
      <PYSalariesCompEmpBnftPaidAmt>6762079</PYSalariesCompEmpBnftPaidAmt>
      <CYSalariesCompEmpBnftPaidAmt>8601831</CYSalariesCompEmpBnftPaidAmt>
      <PYTotalProfFndrsngExpnsAmt>0</PYTotalProfFndrsngExpnsAmt>
      <CYTotalProfFndrsngExpnsAmt>0</CYTotalProfFndrsngExpnsAmt>
      <CYTotalFundraisingExpenseAmt>40673</CYTotalFundraisingExpenseAmt>
      <PYOtherExpensesAmt>3456621</PYOtherExpensesAmt>
      <CYOtherExpensesAmt>4233682</CYOtherExpensesAmt>
      <PYTotalExpensesAmt>11004747</PYTotalExpensesAmt>
      <CYTotalExpensesAmt>14722316</CYTotalExpensesAmt>
      <PYRevenuesLessExpensesAmt>-665965</PYRevenuesLessExpensesAmt>
      <CYRevenuesLessExpensesAmt>3236499</CYRevenuesLessExpensesAmt>
      <TotalAssetsBOYAmt>3193164</TotalAssetsBOYAmt>
      <TotalAssetsEOYAmt>5921898</TotalAssetsEOYAmt>
      <TotalLiabilitiesBOYAmt>1753320</TotalLiabilitiesBOYAmt>
      <TotalLiabilitiesEOYAmt>1245555</TotalLiabilitiesEOYAmt>
      <NetAssetsOrFundBalancesBOYAmt>1439844</NetAssetsOrFundBalancesBOYAmt>
      <NetAssetsOrFundBalancesEOYAmt>4676343</NetAssetsOrFundBalancesEOYAmt>
      <MissionDesc>Sage Bionetworks is a strategic research organization with a mission to coordinate and link academic and commercial biomedical researchers, patients and citizens through a Commons that represents a new paradigm for genomics intellectual property, researcher cooperation and contributor evolved resources. This mission has several interdependent themes, including: conducting research on network models of disease; building the computational platform for the Commons; and activating public engagement. Sage Bionetworks is a non-profit research organization that seeks to develop predictors of disease and accelerate health research through the creation of open systems, incentives, and standards. We create strategies and platforms that empower researchers to share and interpret data on a colossal scale, crowdsource tests for new hypotheses, and contribute to knowledge through community challenges.</MissionDesc>
      <SignificantNewProgramSrvcInd>0</SignificantNewProgramSrvcInd>
      <SignificantChangeInd>0</SignificantChangeInd>
      <ExpenseAmt>9647005</ExpenseAmt>
      <GrantAmt>7068028</GrantAmt>
      <RevenueAmt>10893528</RevenueAmt>
      <Desc>Research Communities and Challenges: Sage Bionetworks conducts research independently as well as with collaborators worldwide across a variety of disease areas. We work to redefine how complex biological data is gathered, shared and used through open systems, incentives, and norms. Our work includes the building of platforms and services and undertaking research developing predictors relating to health. Research: As biological research has become more data intensive, the breadth of data and expertise required to address research problems has expanded. It requires the integrated efforts of a distributed set of researchers (such as bench/data scientists, data engineers, project managers, administrators, governance experts, and clinical researchers) with shared interests and complementary resources. Effective collaboration depends on a collective ability to work together in trusted ways that lead to translatable biomedical insights. We call this scientific coordination. Sage's scientific coordination stack includes: 1) hypothesis and data generation, 2) data curation, 3) analysis, 4) interpretation, and 5) dissemination. We focus on building a federated network of individuals who bring diverse expertise and approaches to develop robust solutions. New research projects initiated in 2018 included: * Human Tumor Atlas Network (HTAN) - Funded by NCI, Sage is the data coordinating center for HTAN which aims to leverage the power of human genome sequencing and other state-of-the-art profiling technologies, to analyze changes in individual tumors. * VEOIBD Portal - Funded by the Helmsley Charitable Trust, the VEOIBD Portal aggregates Consortium-identified genotypic data with data from other data sources to find causes and treatments for Inflammatory Bowel Disease (IBD). Ongoing research communities included: * Agora - funded by the NIA, Agora is a platform that enables researchers to access information about how genes are associated with Alzheimer's disease. It aggregates lines of biological evidence from multiple sources, so researchers can better prioritize which genes they want to follow up on for development of new therapies. * All of Us - a program to engage over one million participants in a study to improve the ability to prevent and treat disease based on individual differences in lifestyle, environment and genetics. * CD2H (National Center for Data to Health) - with aims to foster collaboration across more than 50 premier medical research institutions within the prestigious Clinical and Translational Science Awards, or CTSA, network. * Cancer Systems Biology Consortium (CSBC) - Sage serves as the Coordinating Center for the CSBC and Physical Sciences in Oncology Network (PS-ON) program. This five-year award builds on the work of the NCI funded Sage Bionetworks' Center for Cancer Systems Biology from 2010 through 2015. * iAtlas -together with the Institute for Systems Biology, Sage was funded by the Cancer Research Institute to build iAtlas, an online database and web resource designed to help basic and clinical researchers navigate immunological data across multiple tumor types. * KiAAP - funded by Bill and Melinda Gates Foundation, Sage was engaged to support the distributed efforts of BMGF funded data scientists across a number of ongoing research projects in neurocognitive development. * MODEL-AD Consortium - Sage runs the Knowledge Portal, the distribution site for data, analysis results, analytical methodology and research tools generated by the AMP-AD and M2OVE-AD Consortia. * Synodos Consortium - a first-of-its-kind Neurofibromatosis research collaboration dedicated to defeating the rare genetic disorder neurofibromatosis type 2. * The Cancer Genome Atlas (TCGA) - with data from 12 cancers, TCGA is an ongoing effort to simultaneously analyze molecular platforms for patterns across cancer types. * Tumor Neoantigen Selection Alliance (TESLA) - a global research alliance with 30 public and private groups to advance the development of more effective personalized cancer treatments. Funded by the Parker Institute for Cancer. Challenges: With algorithms playing an increasing role in biomedical analysis and patient care, there's a need for a more rigorous framework for evaluating and improving the capabilities of these algorithms. Sage Bionetworks has pioneered the development of concepts and infrastructure to objectively evaluate algorithms across a broad spectrum of biomedical domains, including bioinformatics, biomedical informatics, and clinical trials. As a trusted partner in hosting challenges and benchmarking initiatives, Sage serves as a broker between data generators and data modelers. We combine technology with biomedical and data science expertise to facilitate the objective assessment of algorithms on critical data sets, including proprietary data and algorithms that cannot be broadly shared. Sage works with the DREAM community to host open challenges. With 13 years of successful Challenges, DREAM is recognized as a leader in biomedical competitions, successfully motivating research teams to address fundamental questions about systems biology and translational medicine and to advance computational methods. DREAM challenges invite participants to propose solutions - fostering collaboration and building communities in the process. Over 20,000 people from around the world and across disciplines have contributed their expertise to Challenges. Sage Bionetworks provides institutional support, along with the infrastructure to host challenges via our Synapse platform Active Challenges hosted on the Synapse platform in 2018 included: * ACIC 2018 Causal Inference Challenge -held at the annual Atlantic Causal Inference Conference (ACIC), participants of this challenge focused on computational methods of inferring causal effects from real-world healthcare-related data. * DREAM Single Cell Transcriptomics Challenge - participants were asked to reconstruct the location of single cells in the Drosophila embryo using single-cell transcriptomic data. * IDG Drug-Kinase Binding Challenge - seeks to evaluate the power of statistical and machine learning models as a systematic and cost-effective means for catalyzing compound-target interaction mapping efforts. * Multi-targeting Drug DREAM Challenge - seeks to diversify the methods used for rational design of drugs with multiple target proteins.</Desc>
      <ProgSrvcAccomActy2Grp>
        <ExpenseAmt>4414233</ExpenseAmt>
        <GrantAmt>3554233</GrantAmt>
        <RevenueAmt>4984896</RevenueAmt>
        <Desc>Digital Health Smartphones and other wearable sensors have put touchscreens and high-fidelity sensors into the pockets of billions of people. These technologies provide an opportunity to paint a rich understanding of health and disease in the everyday world outside of the clinic. They also provide communication tools that allow participants a more active voice in research programs. With our Digital Health program, we work to advance health research through practices that support the design, development and implementation of studies that use technology to monitor health outside of the clinical setting, and the analysis and sharing of the resulting study data. We help to derive and test digital biomarkers. We evaluate analytical methodologies to benchmark best practices in study design and data analysis. Sage's Digital Health program is built around Bridge, a technology platform for conducting biomedical research studies primarily using the ResearchKit (iOS) and ResearchStack (Android) frameworks. Bridge is composed of HIPAA-compliant web services and multi-language SDKs that facilitate: registration and informed consent to participate in research; web-based tools to design and schedule study surveys and sensor-based tasks; acquisition and secure transfer of multiple data types (surveys, sensors, audio, video, or custom data types); a study management portal with daily dashboard updates; and de-identification and storage of study data in our collaborative data science environment, Synapse. Digital Health studies active in 2018 included: * Cardiovascular Fitness Module - As part of the PMI All of Us study, Sage is developing methods to use the sensors built into smartphones to assess Cardiorespiratory fitness in a way that can scale to potentially one million participants and become a generally useful tool for clinical research. * Chronic Anemia - conducted in partnership with Celgene, Journey PRO incorporates wearable and mobile technologies to assess mobility, cardiovascular health, cognitive performance, and quality of life assessments. * Multiple Sclerosis - with pharmaceutical partner Novartis, Sage launched elevateMS, a mobile app to monitor the severity of MS symptoms and to track relapse * Sage, together with study partners at OHSU, publicly released the first data set from the Mole Mapper melanoma mobile health study. * mPower Public Researcher Portal - an updated version of the mPower iPhone study piloting new approaches to monitoring key indicators of Parkinson Disease was active in 2018. A subset of data from this portal along with data contributed by MJFF was included in the PD Digital Biomarker DREAM Challenge launched in 2017.</Desc>
      </ProgSrvcAccomActy2Grp>
      <TotalOtherProgSrvcExpenseAmt>0</TotalOtherProgSrvcExpenseAmt>
      <TotalOtherProgSrvcGrantAmt>0</TotalOtherProgSrvcGrantAmt>
      <TotalOtherProgSrvcRevenueAmt>0</TotalOtherProgSrvcRevenueAmt>
      <TotalProgramServiceExpensesAmt>14061238</TotalProgramServiceExpensesAmt>
      <DescribedInSection501c3Ind referenceDocumentId="R000002">1</DescribedInSection501c3Ind>
      <ScheduleBRequiredInd referenceDocumentId="R000003">1</ScheduleBRequiredInd>
      <PoliticalCampaignActyInd>0</PoliticalCampaignActyInd>
      <LobbyingActivitiesInd>0</LobbyingActivitiesInd>
      <SubjectToProxyTaxInd>0</SubjectToProxyTaxInd>
      <DonorAdvisedFundInd>0</DonorAdvisedFundInd>
      <ConservationEasementsInd>0</ConservationEasementsInd>
      <CollectionsOfArtInd>0</CollectionsOfArtInd>
      <CreditCounselingInd>0</CreditCounselingInd>
      <TempOrPermanentEndowmentsInd>0</TempOrPermanentEndowmentsInd>
      <ReportLandBuildingEquipmentInd referenceDocumentId="R000004">1</ReportLandBuildingEquipmentInd>
      <ReportInvestmentsOtherSecInd>0</ReportInvestmentsOtherSecInd>
      <ReportProgramRelatedInvstInd>0</ReportProgramRelatedInvstInd>
      <ReportOtherAssetsInd referenceDocumentId="R000004">1</ReportOtherAssetsInd>
      <ReportOtherLiabilitiesInd referenceDocumentId="R000004">1</ReportOtherLiabilitiesInd>
      <IncludeFIN48FootnoteInd>0</IncludeFIN48FootnoteInd>
      <IndependentAuditFinclStmtInd referenceDocumentId="R000004">1</IndependentAuditFinclStmtInd>
      <ConsolidatedAuditFinclStmtInd referenceDocumentId="R000004">0</ConsolidatedAuditFinclStmtInd>
      <SchoolOperatingInd>0</SchoolOperatingInd>
      <ForeignOfficeInd>0</ForeignOfficeInd>
      <ForeignActivitiesInd referenceDocumentId="R000005">1</ForeignActivitiesInd>
      <MoreThan5000KToOrgInd referenceDocumentId="R000005">1</MoreThan5000KToOrgInd>
      <MoreThan5000KToIndividualsInd>0</MoreThan5000KToIndividualsInd>
      <ProfessionalFundraisingInd>0</ProfessionalFundraisingInd>
      <FundraisingActivitiesInd>0</FundraisingActivitiesInd>
      <GamingActivitiesInd>0</GamingActivitiesInd>
      <OperateHospitalInd>0</OperateHospitalInd>
      <GrantsToOrganizationsInd referenceDocumentId="R000006">1</GrantsToOrganizationsInd>
      <GrantsToIndividualsInd>0</GrantsToIndividualsInd>
      <ScheduleJRequiredInd referenceDocumentId="R000007">1</ScheduleJRequiredInd>
      <TaxExemptBondsInd>0</TaxExemptBondsInd>
      <EngagedInExcessBenefitTransInd>0</EngagedInExcessBenefitTransInd>
      <PYExcessBenefitTransInd>0</PYExcessBenefitTransInd>
      <LoanOutstandingInd>0</LoanOutstandingInd>
      <GrantToRelatedPersonInd>0</GrantToRelatedPersonInd>
      <BusinessRlnWithOrgMemInd>0</BusinessRlnWithOrgMemInd>
      <BusinessRlnWithFamMemInd>0</BusinessRlnWithFamMemInd>
      <BusinessRlnWithOfficerEntInd>0</BusinessRlnWithOfficerEntInd>
      <DeductibleNonCashContriInd referenceDocumentId="R000008">1</DeductibleNonCashContriInd>
      <DeductibleArtContributionInd>0</DeductibleArtContributionInd>
      <TerminateOperationsInd>0</TerminateOperationsInd>
      <PartialLiquidationInd>0</PartialLiquidationInd>
      <DisregardedEntityInd>0</DisregardedEntityInd>
      <RelatedEntityInd>0</RelatedEntityInd>
      <RelatedOrganizationCtrlEntInd>0</RelatedOrganizationCtrlEntInd>
      <TrnsfrExmptNonChrtblRltdOrgInd>0</TrnsfrExmptNonChrtblRltdOrgInd>
      <ActivitiesConductedPrtshpInd>0</ActivitiesConductedPrtshpInd>
      <ScheduleORequiredInd>1</ScheduleORequiredInd>
      <IRPDocumentCnt>19</IRPDocumentCnt>
      <IRPDocumentW2GCnt>0</IRPDocumentW2GCnt>
      <EmployeeCnt>71</EmployeeCnt>
      <EmploymentTaxReturnsFiledInd>1</EmploymentTaxReturnsFiledInd>
      <UnrelatedBusIncmOverLimitInd>0</UnrelatedBusIncmOverLimitInd>
      <ForeignFinancialAccountInd>0</ForeignFinancialAccountInd>
      <ProhibitedTaxShelterTransInd>0</ProhibitedTaxShelterTransInd>
      <TaxablePartyNotificationInd>0</TaxablePartyNotificationInd>
      <NondeductibleContributionsInd>0</NondeductibleContributionsInd>
      <QuidProQuoContributionsInd>0</QuidProQuoContributionsInd>
      <Form8282PropertyDisposedOfInd>0</Form8282PropertyDisposedOfInd>
      <RcvFndsToPayPrsnlBnftCntrctInd>0</RcvFndsToPayPrsnlBnftCntrctInd>
      <PayPremiumsPrsnlBnftCntrctInd>0</PayPremiumsPrsnlBnftCntrctInd>
      <IndoorTanningServicesInd>0</IndoorTanningServicesInd>
      <SubjToTaxRmnrtnExPrchtPymtInd>0</SubjToTaxRmnrtnExPrchtPymtInd>
      <SubjectToExcsTaxNetInvstIncInd>0</SubjectToExcsTaxNetInvstIncInd>
      <InfoInScheduleOPartVIInd>X</InfoInScheduleOPartVIInd>
      <GoverningBodyVotingMembersCnt>6</GoverningBodyVotingMembersCnt>
      <IndependentVotingMemberCnt>5</IndependentVotingMemberCnt>
      <FamilyOrBusinessRlnInd>0</FamilyOrBusinessRlnInd>
      <DelegationOfMgmtDutiesInd>0</DelegationOfMgmtDutiesInd>
      <ChangeToOrgDocumentsInd>0</ChangeToOrgDocumentsInd>
      <MaterialDiversionOrMisuseInd>0</MaterialDiversionOrMisuseInd>
      <MembersOrStockholdersInd>0</MembersOrStockholdersInd>
      <ElectionOfBoardMembersInd>0</ElectionOfBoardMembersInd>
      <DecisionsSubjectToApprovaInd>0</DecisionsSubjectToApprovaInd>
      <MinutesOfGoverningBodyInd>1</MinutesOfGoverningBodyInd>
      <MinutesOfCommitteesInd>1</MinutesOfCommitteesInd>
      <OfficerMailingAddressInd>0</OfficerMailingAddressInd>
      <LocalChaptersInd>0</LocalChaptersInd>
      <Form990ProvidedToGvrnBodyInd>1</Form990ProvidedToGvrnBodyInd>
      <ConflictOfInterestPolicyInd>1</ConflictOfInterestPolicyInd>
      <AnnualDisclosureCoveredPrsnInd>1</AnnualDisclosureCoveredPrsnInd>
      <RegularMonitoringEnfrcInd>1</RegularMonitoringEnfrcInd>
      <WhistleblowerPolicyInd>1</WhistleblowerPolicyInd>
      <DocumentRetentionPolicyInd>0</DocumentRetentionPolicyInd>
      <CompensationProcessCEOInd>1</CompensationProcessCEOInd>
      <CompensationProcessOtherInd>0</CompensationProcessOtherInd>
      <InvestmentInJointVentureInd>0</InvestmentInJointVentureInd>
      <UponRequestInd>X</UponRequestInd>
      <BooksInCareOfDetail>
        <PersonNm>Diane Gary</PersonNm>
        <PhoneNum>2069288243</PhoneNum>
        <USAddress>
          <AddressLine1Txt>2901 Third Ave Ste 330</AddressLine1Txt>
          <CityNm>Seattle</CityNm>
          <StateAbbreviationCd>WA</StateAbbreviationCd>
          <ZIPCd>98121</ZIPCd>
        </USAddress>
      </BooksInCareOfDetail>
      <Form990PartVIISectionAGrp>
        <PersonNm>Stephen Friend</PersonNm>
        <TitleTxt>Chairman of the Board</TitleTxt>
        <AverageHoursPerWeekRt>1</AverageHoursPerWeekRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Eric Schadt</PersonNm>
        <TitleTxt>Director/Chair of Scientific Advisory Board</TitleTxt>
        <AverageHoursPerWeekRt>1</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Tony Ford-Hutchinson</PersonNm>
        <TitleTxt>Director</TitleTxt>
        <AverageHoursPerWeekRt>1</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Gustavo Stolovitsky</PersonNm>
        <TitleTxt>Director</TitleTxt>
        <AverageHoursPerWeekRt>1</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Tetsu Maruyama</PersonNm>
        <TitleTxt>Director</TitleTxt>
        <AverageHoursPerWeekRt>1</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Lara Mangravite</PersonNm>
        <TitleTxt>President</TitleTxt>
        <AverageHoursPerWeekRt>50</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>245496</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>36644</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Diane Gary</PersonNm>
        <TitleTxt>Secretary</TitleTxt>
        <AverageHoursPerWeekRt>50</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>166446</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>30837</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>John Wilbanks</PersonNm>
        <TitleTxt>Chief Commons Officer</TitleTxt>
        <AverageHoursPerWeekRt>50</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <KeyEmployeeInd>X</KeyEmployeeInd>
        <ReportableCompFromOrgAmt>231848</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>21981</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Mike Kellen</PersonNm>
        <TitleTxt>Chief Technology Officer</TitleTxt>
        <AverageHoursPerWeekRt>50</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <KeyEmployeeInd>X</KeyEmployeeInd>
        <ReportableCompFromOrgAmt>210759</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>23947</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Justin Guinney</PersonNm>
        <TitleTxt>Vice President, Computational Oncology</TitleTxt>
        <AverageHoursPerWeekRt>50</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <KeyEmployeeInd>X</KeyEmployeeInd>
        <ReportableCompFromOrgAmt>195821</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>36057</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Larsson Omberg</PersonNm>
        <TitleTxt>Vice President, Systems Biology</TitleTxt>
        <AverageHoursPerWeekRt>50</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <KeyEmployeeInd>X</KeyEmployeeInd>
        <ReportableCompFromOrgAmt>166446</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>30832</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Bruce Hoff</PersonNm>
        <TitleTxt>Director, Synapse Team</TitleTxt>
        <AverageHoursPerWeekRt>50</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>166334</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>39614</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Erin Mounts</PersonNm>
        <TitleTxt>Principle SW Engineer</TitleTxt>
        <AverageHoursPerWeekRt>50</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>161735</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>30504</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Dwayne Jeng</PersonNm>
        <TitleTxt>Principal SW Engineer</TitleTxt>
        <AverageHoursPerWeekRt>50</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>156897</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>19987</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>Alx Dark</PersonNm>
        <TitleTxt>Principle Software Engineer</TitleTxt>
        <AverageHoursPerWeekRt>50</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>156811</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>11529</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>John Woodburn</PersonNm>
        <TitleTxt>Director, Design</TitleTxt>
        <AverageHoursPerWeekRt>50</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>154831</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>19835</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <TotalReportableCompFromOrgAmt>2013424</TotalReportableCompFromOrgAmt>
      <TotReportableCompRltdOrgAmt>0</TotReportableCompRltdOrgAmt>
      <TotalOtherCompensationAmt>301767</TotalOtherCompensationAmt>
      <IndivRcvdGreaterThan100KCnt>39</IndivRcvdGreaterThan100KCnt>
      <FormerOfcrEmployeesListedInd>0</FormerOfcrEmployeesListedInd>
      <TotalCompGreaterThan150KInd>1</TotalCompGreaterThan150KInd>
      <CompensationFromOtherSrcsInd>0</CompensationFromOtherSrcsInd>
      <ContractorCompensationGrp>
        <ContractorName>
          <PersonNm>Stockard Simon</PersonNm>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>44564 SE 144th St</AddressLine1Txt>
            <CityNm>North Bend</CityNm>
            <StateAbbreviationCd>WA</StateAbbreviationCd>
            <ZIPCd>98045</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>IT Design</ServicesDesc>
        <CompensationAmt>152386</CompensationAmt>
      </ContractorCompensationGrp>
      <ContractorCompensationGrp>
        <ContractorName>
          <PersonNm>Yuangang Guan</PersonNm>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>744 Eagle Ave</AddressLine1Txt>
            <CityNm>Ann Arbor</CityNm>
            <StateAbbreviationCd>MI</StateAbbreviationCd>
            <ZIPCd>48103</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>Scientific challenges</ServicesDesc>
        <CompensationAmt>113917</CompensationAmt>
      </ContractorCompensationGrp>
      <CntrctRcvdGreaterThan100KCnt>2</CntrctRcvdGreaterThan100KCnt>
      <FederatedCampaignsAmt>0</FederatedCampaignsAmt>
      <MembershipDuesAmt>0</MembershipDuesAmt>
      <FundraisingAmt>0</FundraisingAmt>
      <RelatedOrganizationsAmt>0</RelatedOrganizationsAmt>
      <GovernmentGrantsAmt>10622261</GovernmentGrantsAmt>
      <AllOtherContributionsAmt>4933165</AllOtherContributionsAmt>
      <NoncashContributionsAmt>101355</NoncashContributionsAmt>
      <TotalContributionsAmt>15555426</TotalContributionsAmt>
      <ProgramServiceRevenueGrp>
        <Desc>Scientific Collaborations</Desc>
        <BusinessCd>541711</BusinessCd>
        <TotalRevenueColumnAmt>2402775</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>2402775</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>0</ExclusionAmt>
      </ProgramServiceRevenueGrp>
      <TotalOthProgramServiceRevGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>0</ExclusionAmt>
      </TotalOthProgramServiceRevGrp>
      <TotalProgramServiceRevenueAmt>2402775</TotalProgramServiceRevenueAmt>
      <InvestmentIncomeGrp>
        <TotalRevenueColumnAmt>614</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>614</ExclusionAmt>
      </InvestmentIncomeGrp>
      <IncmFromInvestBondProceedsGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>0</ExclusionAmt>
      </IncmFromInvestBondProceedsGrp>
      <RoyaltiesRevenueGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>0</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>0</ExclusionAmt>
      </RoyaltiesRevenueGrp>
      <RentalIncomeOrLossGrp>
        <RealAmt>0</RealAmt>
        <PersonalAmt>0</PersonalAmt>
      </RentalIncomeOrLossGrp>
      <GainOrLossGrp>
        <SecuritiesAmt>0</SecuritiesAmt>
        <OtherAmt>0</OtherAmt>
      </GainOrLossGrp>
      <ContriRptFundraisingEventAmt>0</ContriRptFundraisingEventAmt>
      <OtherRevenueTotalAmt>0</OtherRevenueTotalAmt>
      <TotalRevenueGrp>
        <TotalRevenueColumnAmt>17958815</TotalRevenueColumnAmt>
        <RelatedOrExemptFuncIncomeAmt>2402775</RelatedOrExemptFuncIncomeAmt>
        <UnrelatedBusinessRevenueAmt>0</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>614</ExclusionAmt>
      </TotalRevenueGrp>
      <InfoInScheduleOPartIXInd>X</InfoInScheduleOPartIXInd>
      <GrantsToDomesticOrgsGrp>
        <TotalAmt>1660903</TotalAmt>
        <ProgramServicesAmt>1660903</ProgramServicesAmt>
      </GrantsToDomesticOrgsGrp>
      <GrantsToDomesticIndividualsGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
      </GrantsToDomesticIndividualsGrp>
      <ForeignGrantsGrp>
        <TotalAmt>225900</TotalAmt>
        <ProgramServicesAmt>225900</ProgramServicesAmt>
      </ForeignGrantsGrp>
      <BenefitsToMembersGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
      </BenefitsToMembersGrp>
      <CompCurrentOfcrDirectorsGrp>
        <TotalAmt>1465680</TotalAmt>
        <ProgramServicesAmt>1218969</ProgramServicesAmt>
        <ManagementAndGeneralAmt>235992</ManagementAndGeneralAmt>
        <FundraisingAmt>10719</FundraisingAmt>
      </CompCurrentOfcrDirectorsGrp>
      <CompDisqualPersonsGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
        <ManagementAndGeneralAmt>0</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </CompDisqualPersonsGrp>
      <OtherSalariesAndWagesGrp>
        <TotalAmt>5733150</TotalAmt>
        <ProgramServicesAmt>5505292</ProgramServicesAmt>
        <ManagementAndGeneralAmt>209658</ManagementAndGeneralAmt>
        <FundraisingAmt>18200</FundraisingAmt>
      </OtherSalariesAndWagesGrp>
      <PensionPlanContributionsGrp>
        <TotalAmt>232559</TotalAmt>
        <ProgramServicesAmt>217633</ProgramServicesAmt>
        <ManagementAndGeneralAmt>14278</ManagementAndGeneralAmt>
        <FundraisingAmt>648</FundraisingAmt>
      </PensionPlanContributionsGrp>
      <OtherEmployeeBenefitsGrp>
        <TotalAmt>919508</TotalAmt>
        <ProgramServicesAmt>893899</ProgramServicesAmt>
        <ManagementAndGeneralAmt>23077</ManagementAndGeneralAmt>
        <FundraisingAmt>2532</FundraisingAmt>
      </OtherEmployeeBenefitsGrp>
      <PayrollTaxesGrp>
        <TotalAmt>250934</TotalAmt>
        <ProgramServicesAmt>232870</ProgramServicesAmt>
        <ManagementAndGeneralAmt>17341</ManagementAndGeneralAmt>
        <FundraisingAmt>723</FundraisingAmt>
      </PayrollTaxesGrp>
      <FeesForServicesManagementGrp>
        <TotalAmt>62696</TotalAmt>
        <ProgramServicesAmt>58815</ProgramServicesAmt>
        <ManagementAndGeneralAmt>3643</ManagementAndGeneralAmt>
        <FundraisingAmt>238</FundraisingAmt>
      </FeesForServicesManagementGrp>
      <FeesForServicesLegalGrp>
        <TotalAmt>138472</TotalAmt>
        <ProgramServicesAmt>129901</ProgramServicesAmt>
        <ManagementAndGeneralAmt>8045</ManagementAndGeneralAmt>
        <FundraisingAmt>526</FundraisingAmt>
      </FeesForServicesLegalGrp>
      <FeesForServicesAccountingGrp>
        <TotalAmt>38737</TotalAmt>
        <ProgramServicesAmt>36339</ProgramServicesAmt>
        <ManagementAndGeneralAmt>2251</ManagementAndGeneralAmt>
        <FundraisingAmt>147</FundraisingAmt>
      </FeesForServicesAccountingGrp>
      <FeesForServicesLobbyingGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
        <ManagementAndGeneralAmt>0</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </FeesForServicesLobbyingGrp>
      <FeesForServicesProfFundraising>
        <TotalAmt>0</TotalAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </FeesForServicesProfFundraising>
      <FeesForSrvcInvstMgmntFeesGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
        <ManagementAndGeneralAmt>0</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </FeesForSrvcInvstMgmntFeesGrp>
      <FeesForServicesOtherGrp>
        <TotalAmt>2372299</TotalAmt>
        <ProgramServicesAmt>2355780</ProgramServicesAmt>
        <ManagementAndGeneralAmt>15505</ManagementAndGeneralAmt>
        <FundraisingAmt>1014</FundraisingAmt>
      </FeesForServicesOtherGrp>
      <AdvertisingGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
        <ManagementAndGeneralAmt>0</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </AdvertisingGrp>
      <OfficeExpensesGrp>
        <TotalAmt>49173</TotalAmt>
        <ProgramServicesAmt>46129</ProgramServicesAmt>
        <ManagementAndGeneralAmt>2857</ManagementAndGeneralAmt>
        <FundraisingAmt>187</FundraisingAmt>
      </OfficeExpensesGrp>
      <InformationTechnologyGrp>
        <TotalAmt>160055</TotalAmt>
        <ProgramServicesAmt>150148</ProgramServicesAmt>
        <ManagementAndGeneralAmt>9299</ManagementAndGeneralAmt>
        <FundraisingAmt>608</FundraisingAmt>
      </InformationTechnologyGrp>
      <RoyaltiesGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
        <ManagementAndGeneralAmt>0</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </RoyaltiesGrp>
      <OccupancyGrp>
        <TotalAmt>605854</TotalAmt>
        <ProgramServicesAmt>568352</ProgramServicesAmt>
        <ManagementAndGeneralAmt>35200</ManagementAndGeneralAmt>
        <FundraisingAmt>2302</FundraisingAmt>
      </OccupancyGrp>
      <TravelGrp>
        <TotalAmt>364570</TotalAmt>
        <ProgramServicesAmt>341123</ProgramServicesAmt>
        <ManagementAndGeneralAmt>22008</ManagementAndGeneralAmt>
        <FundraisingAmt>1439</FundraisingAmt>
      </TravelGrp>
      <PymtTravelEntrtnmntPubOfclGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
        <ManagementAndGeneralAmt>0</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </PymtTravelEntrtnmntPubOfclGrp>
      <ConferencesMeetingsGrp>
        <TotalAmt>38378</TotalAmt>
        <ProgramServicesAmt>37287</ProgramServicesAmt>
        <ManagementAndGeneralAmt>1024</ManagementAndGeneralAmt>
        <FundraisingAmt>67</FundraisingAmt>
      </ConferencesMeetingsGrp>
      <InterestGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
        <ManagementAndGeneralAmt>0</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </InterestGrp>
      <PaymentsToAffiliatesGrp>
        <TotalAmt>0</TotalAmt>
        <ProgramServicesAmt>0</ProgramServicesAmt>
        <ManagementAndGeneralAmt>0</ManagementAndGeneralAmt>
        <FundraisingAmt>0</FundraisingAmt>
      </PaymentsToAffiliatesGrp>
      <DepreciationDepletionGrp>
        <TotalAmt>16806</TotalAmt>
        <ProgramServicesAmt>15766</ProgramServicesAmt>
        <ManagementAndGeneralAmt>976</ManagementAndGeneralAmt>
        <FundraisingAmt>64</FundraisingAmt>
      </DepreciationDepletionGrp>
      <InsuranceGrp>
        <TotalAmt>29139</TotalAmt>
        <ProgramServicesAmt>27335</ProgramServicesAmt>
        <ManagementAndGeneralAmt>1693</ManagementAndGeneralAmt>
        <FundraisingAmt>111</FundraisingAmt>
      </InsuranceGrp>
      <AllOtherExpensesGrp>
        <TotalAmt>357503</TotalAmt>
        <ProgramServicesAmt>338797</ProgramServicesAmt>
        <ManagementAndGeneralAmt>17558</ManagementAndGeneralAmt>
        <FundraisingAmt>1148</FundraisingAmt>
      </AllOtherExpensesGrp>
      <TotalFunctionalExpensesGrp>
        <TotalAmt>14722316</TotalAmt>
        <ProgramServicesAmt>14061238</ProgramServicesAmt>
        <ManagementAndGeneralAmt>620405</ManagementAndGeneralAmt>
        <FundraisingAmt>40673</FundraisingAmt>
      </TotalFunctionalExpensesGrp>
      <CashNonInterestBearingGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </CashNonInterestBearingGrp>
      <SavingsAndTempCashInvstGrp>
        <BOYAmt>488278</BOYAmt>
        <EOYAmt>564479</EOYAmt>
      </SavingsAndTempCashInvstGrp>
      <PledgesAndGrantsReceivableGrp>
        <BOYAmt>2570019</BOYAmt>
        <EOYAmt>3134674</EOYAmt>
      </PledgesAndGrantsReceivableGrp>
      <AccountsReceivableGrp>
        <BOYAmt>46969</BOYAmt>
        <EOYAmt>1021718</EOYAmt>
      </AccountsReceivableGrp>
      <ReceivablesFromOfficersEtcGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </ReceivablesFromOfficersEtcGrp>
      <RcvblFromDisqualifiedPrsnGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </RcvblFromDisqualifiedPrsnGrp>
      <OthNotesLoansReceivableNetGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </OthNotesLoansReceivableNetGrp>
      <InventoriesForSaleOrUseGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </InventoriesForSaleOrUseGrp>
      <PrepaidExpensesDefrdChargesGrp>
        <BOYAmt>84143</BOYAmt>
        <EOYAmt>88014</EOYAmt>
      </PrepaidExpensesDefrdChargesGrp>
      <LandBldgEquipCostOrOtherBssAmt>104503</LandBldgEquipCostOrOtherBssAmt>
      <LandBldgEquipAccumDeprecAmt>13208</LandBldgEquipAccumDeprecAmt>
      <LandBldgEquipBasisNetGrp>
        <BOYAmt>3755</BOYAmt>
        <EOYAmt>91295</EOYAmt>
      </LandBldgEquipBasisNetGrp>
      <InvestmentsPubTradedSecGrp>
        <BOYAmt>0</BOYAmt>
      </InvestmentsPubTradedSecGrp>
      <InvestmentsOtherSecuritiesGrp>
        <BOYAmt>0</BOYAmt>
      </InvestmentsOtherSecuritiesGrp>
      <InvestmentsProgramRelatedGrp>
        <BOYAmt>0</BOYAmt>
      </InvestmentsProgramRelatedGrp>
      <IntangibleAssetsGrp>
        <BOYAmt>0</BOYAmt>
      </IntangibleAssetsGrp>
      <OtherAssetsTotalGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>1021718</EOYAmt>
      </OtherAssetsTotalGrp>
      <TotalAssetsGrp>
        <BOYAmt>3193164</BOYAmt>
        <EOYAmt>5921898</EOYAmt>
      </TotalAssetsGrp>
      <AccountsPayableAccrExpnssGrp>
        <BOYAmt>759381</BOYAmt>
        <EOYAmt>750306</EOYAmt>
      </AccountsPayableAccrExpnssGrp>
      <GrantsPayableGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </GrantsPayableGrp>
      <DeferredRevenueGrp>
        <BOYAmt>993939</BOYAmt>
        <EOYAmt>457667</EOYAmt>
      </DeferredRevenueGrp>
      <TaxExemptBondLiabilitiesGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </TaxExemptBondLiabilitiesGrp>
      <EscrowAccountLiabilityGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </EscrowAccountLiabilityGrp>
      <LoansFromOfficersDirectorsGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </LoansFromOfficersDirectorsGrp>
      <MortgNotesPyblScrdInvstPropGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </MortgNotesPyblScrdInvstPropGrp>
      <UnsecuredNotesLoansPayableGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </UnsecuredNotesLoansPayableGrp>
      <OtherLiabilitiesGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>37582</EOYAmt>
      </OtherLiabilitiesGrp>
      <TotalLiabilitiesGrp>
        <BOYAmt>1753320</BOYAmt>
        <EOYAmt>1245555</EOYAmt>
      </TotalLiabilitiesGrp>
      <OrganizationFollowsSFAS117Ind>X</OrganizationFollowsSFAS117Ind>
      <UnrestrictedNetAssetsGrp>
        <BOYAmt>1280854</BOYAmt>
        <EOYAmt>2352896</EOYAmt>
      </UnrestrictedNetAssetsGrp>
      <TemporarilyRstrNetAssetsGrp>
        <BOYAmt>158990</BOYAmt>
        <EOYAmt>2323447</EOYAmt>
      </TemporarilyRstrNetAssetsGrp>
      <PermanentlyRstrNetAssetsGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </PermanentlyRstrNetAssetsGrp>
      <TotalNetAssetsFundBalanceGrp>
        <BOYAmt>1439844</BOYAmt>
        <EOYAmt>4676343</EOYAmt>
      </TotalNetAssetsFundBalanceGrp>
      <TotLiabNetAssetsFundBalanceGrp>
        <BOYAmt>3193164</BOYAmt>
        <EOYAmt>5921898</EOYAmt>
      </TotLiabNetAssetsFundBalanceGrp>
      <ReconcilationRevenueExpnssAmt>3236499</ReconcilationRevenueExpnssAmt>
      <NetUnrlzdGainsLossesInvstAmt>0</NetUnrlzdGainsLossesInvstAmt>
      <DonatedServicesAndUseFcltsAmt>0</DonatedServicesAndUseFcltsAmt>
      <InvestmentExpenseAmt>0</InvestmentExpenseAmt>
      <PriorPeriodAdjustmentsAmt>0</PriorPeriodAdjustmentsAmt>
      <OtherChangesInNetAssetsAmt>0</OtherChangesInNetAssetsAmt>
      <MethodOfAccountingAccrualInd>X</MethodOfAccountingAccrualInd>
      <AccountantCompileOrReviewInd>1</AccountantCompileOrReviewInd>
      <AcctCompileOrReviewBasisGrp>
        <ConsolidatedBasisFinclStmtInd>X</ConsolidatedBasisFinclStmtInd>
      </AcctCompileOrReviewBasisGrp>
      <FSAuditedInd>1</FSAuditedInd>
      <FSAuditedBasisGrp>
        <ConsolidatedBasisFinclStmtInd>X</ConsolidatedBasisFinclStmtInd>
      </FSAuditedBasisGrp>
      <AuditCommitteeInd>1</AuditCommitteeInd>
      <FederalGrantAuditRequiredInd>1</FederalGrantAuditRequiredInd>
      <FederalGrantAuditPerformedInd>1</FederalGrantAuditPerformedInd>
    </IRS990>
    <IRS990ScheduleA documentId="R000002" softwareId="18007995" softwareVersionNum="v1.00">
      <PublicOrganization170Ind>X</PublicOrganization170Ind>
      <GiftsGrantsContriRcvd170Grp>
        <CurrentTaxYearMinus4YearsAmt>7808314</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>6230203</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>5050380</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>7337399</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>12490269</CurrentTaxYearAmt>
        <TotalAmt>38916565</TotalAmt>
      </GiftsGrantsContriRcvd170Grp>
      <TaxRevLeviedOrgnztnlBnft170Grp>
        <CurrentTaxYearMinus4YearsAmt>0</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>0</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>0</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>0</CurrentTaxYearMinus1YearAmt>
        <TotalAmt>0</TotalAmt>
      </TaxRevLeviedOrgnztnlBnft170Grp>
      <GovtFurnSrvcFcltsVl170Grp>
        <CurrentTaxYearMinus4YearsAmt>0</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>0</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>0</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>0</CurrentTaxYearMinus1YearAmt>
        <TotalAmt>0</TotalAmt>
      </GovtFurnSrvcFcltsVl170Grp>
      <TotalCalendarYear170Grp>
        <CurrentTaxYearMinus4YearsAmt>7808314</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>6230203</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>5050380</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>7337399</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>12490269</CurrentTaxYearAmt>
        <TotalAmt>38916565</TotalAmt>
      </TotalCalendarYear170Grp>
      <PublicSupportTotal170Amt>38916565</PublicSupportTotal170Amt>
      <GrossInvestmentIncome170Grp>
        <CurrentTaxYearMinus4YearsAmt>1802</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>1056</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>380</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>258</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>614</CurrentTaxYearAmt>
        <TotalAmt>4110</TotalAmt>
      </GrossInvestmentIncome170Grp>
      <UnrelatedBusinessNetIncm170Grp>
        <CurrentTaxYearMinus4YearsAmt>0</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>0</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>0</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>0</CurrentTaxYearMinus1YearAmt>
        <TotalAmt>0</TotalAmt>
      </UnrelatedBusinessNetIncm170Grp>
      <OtherIncome170Grp>
        <CurrentTaxYearMinus4YearsAmt>1552869</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>1464542</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>2230377</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>3001123</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>2402778</CurrentTaxYearAmt>
        <TotalAmt>10651689</TotalAmt>
      </OtherIncome170Grp>
      <TotalSupportAmt>49572364</TotalSupportAmt>
      <GrossReceiptsRltdActivitiesAmt>0</GrossReceiptsRltdActivitiesAmt>
      <PublicSupportCY170Pct>0.78505</PublicSupportCY170Pct>
      <PublicSupportPY170Pct>0.76345</PublicSupportPY170Pct>
      <ThirtyThrPctSuprtTestsCY170Ind>X</ThirtyThrPctSuprtTestsCY170Ind>
      <Form990ScheduleAPartVIGrp>
        <FormAndLineReferenceDesc>Schedule A, Part II, Line 10</FormAndLineReferenceDesc>
        <ExplanationTxt>Fee for service revenue from research collaborations.</ExplanationTxt>
      </Form990ScheduleAPartVIGrp>
    </IRS990ScheduleA>
    <IRS990ScheduleB documentId="R000003" softwareId="18007995" softwareVersionNum="v1.00" />
    <IRS990ScheduleD documentId="R000004" softwareId="18007995" softwareVersionNum="v1.00">
      <LandGrp>
        <InvestmentCostOrOtherBasisAmt>0</InvestmentCostOrOtherBasisAmt>
        <OtherCostOrOtherBasisAmt>0</OtherCostOrOtherBasisAmt>
        <BookValueAmt>0</BookValueAmt>
      </LandGrp>
      <BuildingsGrp>
        <InvestmentCostOrOtherBasisAmt>0</InvestmentCostOrOtherBasisAmt>
        <OtherCostOrOtherBasisAmt>0</OtherCostOrOtherBasisAmt>
        <DepreciationAmt>0</DepreciationAmt>
        <BookValueAmt>0</BookValueAmt>
      </BuildingsGrp>
      <LeaseholdImprovementsGrp>
        <InvestmentCostOrOtherBasisAmt>0</InvestmentCostOrOtherBasisAmt>
        <OtherCostOrOtherBasisAmt>0</OtherCostOrOtherBasisAmt>
        <DepreciationAmt>0</DepreciationAmt>
        <BookValueAmt>0</BookValueAmt>
      </LeaseholdImprovementsGrp>
      <EquipmentGrp>
        <InvestmentCostOrOtherBasisAmt>104503</InvestmentCostOrOtherBasisAmt>
        <OtherCostOrOtherBasisAmt>0</OtherCostOrOtherBasisAmt>
        <DepreciationAmt>13208</DepreciationAmt>
        <BookValueAmt>91295</BookValueAmt>
      </EquipmentGrp>
      <OtherLandBuildingsGrp>
        <InvestmentCostOrOtherBasisAmt>0</InvestmentCostOrOtherBasisAmt>
        <OtherCostOrOtherBasisAmt>0</OtherCostOrOtherBasisAmt>
        <DepreciationAmt>0</DepreciationAmt>
        <BookValueAmt>0</BookValueAmt>
      </OtherLandBuildingsGrp>
      <TotalBookValueLandBuildingsAmt>91295</TotalBookValueLandBuildingsAmt>
      <OtherAssetsOrgGrp>
        <Desc>Pledges Receivable, net of current portion</Desc>
        <BookValueAmt>1021718</BookValueAmt>
      </OtherAssetsOrgGrp>
      <TotalBookValueOtherAssetsAmt>1021718</TotalBookValueOtherAssetsAmt>
      <FederalIncomeTaxLiabilityAmt>0</FederalIncomeTaxLiabilityAmt>
      <OtherLiabilitiesOrgGrp>
        <Desc>Deferred building rent</Desc>
        <Amt>37582</Amt>
      </OtherLiabilitiesOrgGrp>
      <TotalLiabilityAmt>37582</TotalLiabilityAmt>
      <TotalRevEtcAuditedFinclStmtAmt>17958815</TotalRevEtcAuditedFinclStmtAmt>
      <NetUnrealizedGainsInvstAmt>0</NetUnrealizedGainsInvstAmt>
      <DonatedServicesAndUseFcltsAmt>0</DonatedServicesAndUseFcltsAmt>
      <RecoveriesPriorYearGrantsAmt>0</RecoveriesPriorYearGrantsAmt>
      <OtherRevenueAmt>0</OtherRevenueAmt>
      <RevenueNotReportedAmt>0</RevenueNotReportedAmt>
      <RevenueSubtotalAmt>17958815</RevenueSubtotalAmt>
      <InvestmentExpensesNotIncldAmt>0</InvestmentExpensesNotIncldAmt>
      <OtherRevenuesNotIncludedAmt>0</OtherRevenuesNotIncludedAmt>
      <RevenueNotReportedFinclStmtAmt>0</RevenueNotReportedFinclStmtAmt>
      <TotalRevenuePerForm990Amt>17958815</TotalRevenuePerForm990Amt>
      <TotExpnsEtcAuditedFinclStmtAmt>14722316</TotExpnsEtcAuditedFinclStmtAmt>
      <DonatedServicesUseFcltsAmt>0</DonatedServicesUseFcltsAmt>
      <PriorYearAdjustmentsAmt>0</PriorYearAdjustmentsAmt>
      <LossesReportedAmt>0</LossesReportedAmt>
      <OtherExpensesIncludedAmt>0</OtherExpensesIncludedAmt>
      <ExpensesNotReportedAmt>0</ExpensesNotReportedAmt>
      <ExpensesSubtotalAmt>14722316</ExpensesSubtotalAmt>
      <InvestmentExpensesNotIncld2Amt>0</InvestmentExpensesNotIncld2Amt>
      <OtherExpensesNotIncludedAmt>0</OtherExpensesNotIncludedAmt>
      <ExpensesNotRptFinclStmtAmt>0</ExpensesNotRptFinclStmtAmt>
      <TotalExpensesPerForm990Amt>14722316</TotalExpensesPerForm990Amt>
    </IRS990ScheduleD>
    <IRS990ScheduleF documentId="R000005" softwareId="18007995" softwareVersionNum="v1.00">
      <GrantRecordsMaintainedInd>1</GrantRecordsMaintainedInd>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>Europe (including Iceland and Greenland)</RegionTxt>
        <OfficesCnt>0</OfficesCnt>
        <EmployeeCnt>0</EmployeeCnt>
        <TypeOfActivitiesConductedTxt>Grantmaking</TypeOfActivitiesConductedTxt>
        <SpecificServicesProvidedTxt>Data generation for our Coordinated biocomputational studies. To enable testing of the therapeutic hypothesis, and to further prioritize targets for more extensive drug development programs, we will develop a toolkit of experimental reagents and data - termed a Target Enabling Package (TEP) - for 10 AMP-AD targets. The TEP is meant to bridge the gap between identification of candidate targets, and the ability to launch a chemical biology or drug discovery program. A TEP will typically include purified protein, biochemical assays, crystal structures, and tool compounds. In some cases, the TEP will identify sequences for mutation in CRISPR/Cas9 loss-of function editing, but in most cases it will enable the initiation of a small molecule chemical probe or antibody discovery project by proving that the target is tractable and reducing the barrier to drug discovery.</SpecificServicesProvidedTxt>
        <RegionTotalExpendituresAmt>225900</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <TotalOfficeCnt>0</TotalOfficeCnt>
      <TotalEmployeeCnt>0</TotalEmployeeCnt>
      <TotalSpentAmt>225900</TotalSpentAmt>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>To enable testing of the therapeutic hypothesis, and to further prioritize targets for more extensive drug development programs, we will develop a toolkit of experimental reagents and data - termed a Target Enabling Package (TEP) - for 10 AMP-AD targets. All TEP components will be openly distributed as described in the resource sharing plan. Our previous experience of over a dozen TEP programs indicates that the availability of therapeutic hypothesis, evidence of druggability, and initial chemical hits for a new target will tempt a wide spectrum of medicinal chemists to launch more extensive chemical development programs.</PurposeOfGrantTxt>
        <CashGrantAmt>162928</CashGrantAmt>
        <MannerOfCashDisbursementTxt>Wire Transfer</MannerOfCashDisbursementTxt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>Serve as experts in DREAM challenge organization, participate in designing the CTPAC-DREAM Proteogenomics Challenge, testing the challenge by doing the initial analysis (dry run), scoring participants submissions, and performing the sub-challenge metaanalysis of results.</PurposeOfGrantTxt>
        <CashGrantAmt>39220</CashGrantAmt>
        <MannerOfCashDisbursementTxt>Wire Transfer</MannerOfCashDisbursementTxt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
      </GrantsToOrgOutsideUSGrp>
      <GrantsToOrgOutsideUSGrp>
        <RegionTxt>Europe (including Iceland and Greenland)</RegionTxt>
        <PurposeOfGrantTxt>Complete gene expression characterization of CRC cell lines and PDX models as well as in silico pharmacogenetic studies in cell lines. Complete xenotrials in molecularly stratified models and receive most of the clinical molecular data from collaborating pharma/academia clinical trials in order to perform correlative predictive and prognostic analyses. Complete data analysis from xenotrials, treatment biomarker interactions from clinical trials and summarize findings with the "investigator-driven' molecularly stratified clinical trial proposals to run in parallel of the MoTriColor study</PurposeOfGrantTxt>
        <CashGrantAmt>23752</CashGrantAmt>
        <MannerOfCashDisbursementTxt>Wire Transfer</MannerOfCashDisbursementTxt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
      </GrantsToOrgOutsideUSGrp>
      <Total501c3OrgCnt>0</Total501c3OrgCnt>
      <TotalOtherOrgCnt>3</TotalOtherOrgCnt>
      <TransferToForeignCorpInd>0</TransferToForeignCorpInd>
      <InterestInForeignTrustInd>0</InterestInForeignTrustInd>
      <ForeignCorpOwnershipInd>0</ForeignCorpOwnershipInd>
      <PassiveForeignInvestmestCoInd>0</PassiveForeignInvestmestCoInd>
      <ForeignPartnershipInd>0</ForeignPartnershipInd>
      <BoycottCountriesInd>0</BoycottCountriesInd>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule F, Part I, Line 2</FormAndLineReferenceDesc>
        <ExplanationTxt>Monitoring the use of grant funds: In some cases, grants received by Sage Bionetworks are passed on to sub-recipients through a sub-award agreement. The Grant Manager is responsible for initiating the sub-award agreement after obtaining budget approval from the PI and Operations Director. In issuing a sub-award, the Grant Manager is responsible for: obtaining verification of the sub-awardee's facilities and administrative rates and Single Audit Reports; reviewing the prime award special terms and conditions to determine whether they are applicable to the sub-award; and determining whether the sub-awardee meets all of the other administrative and regulatory requirements of the prime award. Once the sub-award has been issued, the Grant Manager is responsible for forwarding the fully executed sub-award documents to the Accounting Manager to ensure proper billing. Payments are made only after the sub-award agreement has been fully executed by both parties.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleF>
    <IRS990ScheduleI documentId="R000006" softwareId="18007995" softwareVersionNum="v1.00">
      <GrantRecordsMaintainedInd>1</GrantRecordsMaintainedInd>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Institute for Systems Biology</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>401 Terry Ave N</AddressLine1Txt>
          <CityNm>Seattle</CityNm>
          <StateAbbreviationCd>WA</StateAbbreviationCd>
          <ZIPCd>98109</ZIPCd>
        </USAddress>
        <RecipientEIN>912003593</RecipientEIN>
        <CashGrantAmt>489494</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>Assist in the development of an integrative platform: the Pan-cancer Immune Atlas (iAtlas) to host the data and results derived from the PanCancerAtlas Immune Response Working Group and to provide external investigators witht the ability to reproduce results of the IRWG. Provide expertise related to the analyses of the metabolic and transcriptional regulatory networksand will work collaboratively to develop, implement, test, and benchmark all methods related to the dynamic analyses of the transcriptional regulatory and metabolic networks aimed at drug target discovery for Alzheimer's Disease. The Institute for Systems Biology will provide expertise related to the (dynamic) analyses of the metabolic and transcriptional regulatory networks and will work collaboratively to develop, implement, test, and benchmark all methods related to the dynamic analyses of the transcriptional regulatory and metabolic networks aimed at drug target discovery for the AMP-AD CC project.</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Icahn School of Medicine at Mount Sinai</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1 Gustave L Levy Place</AddressLine1Txt>
          <CityNm>New York</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>11029</ZIPCd>
        </USAddress>
        <RecipientEIN>136171197</RecipientEIN>
        <CashGrantAmt>325616</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>Perform computational and integrative analysis of the AMP/AD data sets to develop a set of high probability therapeutic targets necessary for their assessment and integration into drug discovery efforts for the Agora project. Image-guided studies to determine the contribution of breast cancer cells to metastatic outgrowth Leukemias for the CSBC project.</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>University of California San Diego</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>9500 Gilman Dr</AddressLine1Txt>
          <CityNm>La Jolla</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>92093</ZIPCd>
        </USAddress>
        <RecipientEIN>956006144</RecipientEIN>
        <CashGrantAmt>206908</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>To determine the test validity and test-retest reliability of smartphone-based measurement of CRF. To evaluate the feasibility and acceptability of using a smartphone application to measure CRF. This will be examined using a system usability scale and assessing compliance and overall satisfaction with the administered protocol. Provide expert consultation in the use of agile science methods for creating strategies for facilitating sustained engagement with the MPower 2.0 application. This includes providing expertise related to behavioral theory, human centered design, and measurement strategies. Develop an experimental design and broader strategy for gathering evidence to foster iterative improvement on mPower to foster improved sustained engagement with the tool.</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Stanford University</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>450 Serra Mall</AddressLine1Txt>
          <CityNm>Stanford</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>94305</ZIPCd>
        </USAddress>
        <RecipientEIN>941156365</RecipientEIN>
        <CashGrantAmt>175960</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>Oversee the genomic profiling, analysis, and computational modeling of metastatic colorectal cancer patient data. Prioritize candidate metastasisassociated genes and provide for modeling in organoids. Contribute to the analysis of cell fitness and clone size distributions in the metastatic colon organoid models. Interpret the data from the microenvironmental arrays. Create a baseline model for future comparison using existing framework for Digital Mammography Challenge.</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Fred Hutchinson Cancer Research Center</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1100 Fairview Ave N</AddressLine1Txt>
          <CityNm>Seattle</CityNm>
          <StateAbbreviationCd>WA</StateAbbreviationCd>
          <ZIPCd>98109</ZIPCd>
        </USAddress>
        <RecipientEIN>237156071</RecipientEIN>
        <CashGrantAmt>56144</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>Study the mechanisms that underlie metastatic castrate resistant prostate cancer(CRPC). We will combine approaches from pharmacology, as well as cell and computational biology to identify kinases that are functionally important for driving cell growth and proliferation in CRPC. We will employ Kinome regression approach to: (1) identify kinases in CRPC cell lines and patient-derived organoid models and test in silico predicted candidate kinase inhibitors in 3D bone-mimetic cultures; and (2) validate the effect of candidate kinase inhibitors in in vivo CRPC bone metastasis models, followed by molecular characterization.</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>University of Pittsburgh</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>116 Atwood St</AddressLine1Txt>
          <AddressLine2Txt>Suite 201</AddressLine2Txt>
          <CityNm>Pittsburgh</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>152133402</ZIPCd>
        </USAddress>
        <RecipientEIN>250965591</RecipientEIN>
        <CashGrantAmt>56016</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>Combine approaches from pharmacology, as well as cell and computational biology to identify specific kinases that are functionally important for the growth of metastatic CRPC. We will also build a computational model to predict response to &gt;300 naive kinase inhibitors in a physiological-relevant CRPC bone metastasis model. Further, we will probe the spatial nature of the kinase-driven signaling patterns in the tumors, which is critical to understanding the mechanisms of drug response. Overall, these studies have a strong potential to advance medical practices; a new therapeutic option for metastatic CRPC could give unprecedented hope to the providers and patients who currently face this disease with severely limited alternatives.</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>The University of Texas MD Anderson Cancer Center</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>PO Box 4486</AddressLine1Txt>
          <CityNm>Houston</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>77210</ZIPCd>
        </USAddress>
        <RecipientEIN>746001118</RecipientEIN>
        <CashGrantAmt>55976</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>Validate in 3D the top kinase inhibitors selected in the 2D screening. These experiments will be performed on up to 3 prostate cancer cellular models, including cell lines and patient-derived xenografts, testing different concentration of the inhibitors.</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Duke University</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>324 Blackwell St</AddressLine1Txt>
          <AddressLine2Txt>Ste 850</AddressLine2Txt>
          <CityNm>Durham</CityNm>
          <StateAbbreviationCd>NC</StateAbbreviationCd>
          <ZIPCd>277013659</ZIPCd>
        </USAddress>
        <RecipientEIN>560532129</RecipientEIN>
        <CashGrantAmt>52160</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>Metastasis is the primary cause of cancer patient mortality and is virtually uncurable. In colorectal cancer (CRC), which represents the third leading cause of cancer-related mortality in the United States, 10-20% of patients with Stage II disease and 50% with Stage III develop recurrence, while another 20% of patients present with metastases at diagnosis. Current targeted therapies for metastatic colorectal cancer (mCRC) prolong survival by mere months with little benefit in the adjuvant setting. Improved treatment strategies are thus urgently needed, but require characterization of the molecular drivers and microenvironmental determinants of the metastatic phenotype. Critically, the advent of advanced genome-engineering and lineage tracing technologies, 3-D organotypic culture systems and platforms to probe the tumor microenvironment provides an unprecedented opportunity for rapid, functional and phenotypic screens towards delineation of the genotype-phenotype map in cancer.</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Partners Healthcare System Inc</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>399 Revolution Dr</AddressLine1Txt>
          <AddressLine2Txt>Ste 645</AddressLine2Txt>
          <CityNm>Somerville</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>021451465</ZIPCd>
        </USAddress>
        <RecipientEIN>270273715</RecipientEIN>
        <CashGrantAmt>47732</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>Combine mouse mammary cancer models with high-resolution imaging to quantify early vs late disseminated cancer cells, outgrown metastases, and their colocalization and dynamics. To quantify behavior of disseminated cancer cells using laser scanning confocal microscopy and other techniques available at the MGH Center for Systems Biology.</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>University of Massachusetts Worcester</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>55 Lake Ave N</AddressLine1Txt>
          <CityNm>Worcester</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>016550002</ZIPCd>
        </USAddress>
        <RecipientEIN>043167352</RecipientEIN>
        <CashGrantAmt>46255</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>There is an ongoing debate concerning whether early DCCs or late DCCs drive metastasis during the life of a patient when both population will likely co-exist. We hypothesize that in fact both early and late disseminated cancer cells (DCCs) cooperate to drive metastatic outgrowth. Here, we adopt an innovative interdisciplinary approach combining metastatic tumor modeling, tissue engineering, high-resolution in vivo microscopy, and integrative omics analysis to tackle the problem. We believe the success of this pilot proposal will provide novel strategies to combat the deadly metastatic diseases, as well as foster our future collaborations.</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>University of Arizona</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>220 W 6th St</AddressLine1Txt>
          <CityNm>Tucson</CityNm>
          <StateAbbreviationCd>AZ</StateAbbreviationCd>
          <ZIPCd>85701</ZIPCd>
        </USAddress>
        <RecipientEIN>742652689</RecipientEIN>
        <CashGrantAmt>38685</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>The goal of the project is to develop small molecules (from in silico docking on the CD44 binding pocket and peptidomimetics of CD44 peptide) and peptides (from the peptide array) to disrupt the interaction between CD44 and FERM domain-containing proteins. These tools will help to define if the proteins are druggable, and whether targeting protein-protein interactions can have a more specific effects than global inhibition of the ectodomain of CD44 using antibodies or small molecules. This will pave the way to testing therapeutic hypotheses for AMP-AD targets relating to protein-protein interactions.</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Rutgers the State University of New Jersey</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>33 Knightsbridge Rd</AddressLine1Txt>
          <AddressLine2Txt>Room B112</AddressLine2Txt>
          <CityNm>Piscataway</CityNm>
          <StateAbbreviationCd>NJ</StateAbbreviationCd>
          <ZIPCd>088543925</ZIPCd>
        </USAddress>
        <RecipientEIN>226001086</RecipientEIN>
        <CashGrantAmt>36570</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>The research proposal outlines image-guided studies to determine the contribution of breast disseminated cancer cells to metastatic outgrowth.</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Oregon Health &amp; Science University</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>3181 SW Sam Jackson Park Rd</AddressLine1Txt>
          <AddressLine2Txt>L106OPAM</AddressLine2Txt>
          <CityNm>Portland</CityNm>
          <StateAbbreviationCd>OR</StateAbbreviationCd>
          <ZIPCd>972393908</ZIPCd>
        </USAddress>
        <RecipientEIN>931176109</RecipientEIN>
        <CashGrantAmt>21269</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>CSBC Pilot testing and optimization of MCAT/Her2 crainbow cells on MEMA platform and MEMA optimization and screening.</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>San Ysidro Health</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1601 Precision Park Lane</AddressLine1Txt>
          <CityNm>San Diego</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>92173</ZIPCd>
        </USAddress>
        <RecipientEIN>952801772</RecipientEIN>
        <CashGrantAmt>19929</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>San Ysidro Health (SYHealth) will participate in the "All of Us Research Program Sage Bionetworks - Federally Qualified Health Centers Consent Study" for participant recruitment and data collection. Findings from this study will be used immediately to improve, elaborate, and/or supplement AoURP informed consent materials for AoURP national launch. The project begins with formative work to determine study approach and contribute to study protocols and ends with data submission and analysis verification by the site PI.</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>Hudson River Healthcare Foundation</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1037 Main St</AddressLine1Txt>
          <CityNm>Peekskill</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>105662913</ZIPCd>
        </USAddress>
        <RecipientEIN>200151252</RecipientEIN>
        <CashGrantAmt>18845</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>Research Assistants (RAs) will recruit potential participants using a variety of techniques including engagement tabling in Barham House, a senior apartment building, at the Peekskill Kiley Center with the Community Action Program, and at local community venues like the Salvation Army, the Peekskill Library, and a local homeless shelter, in addition to health-center based recruitment. The RAs and Pilot Coordinator will liaise with community stakeholders to coordinate such recruitment efforts. Interested individuals are screened by RAs using the REALM-SF tool and, if eligible, invited to participate in a 1:1 interview or a focus group. Each session lasts approximately 1 hour and is facilitated and recorded by a Research Assistant. An additional RA participates for notetaking purposes as appropriate. In addition to these implementation activities, our PIs and Project Coordinators liaise with the other FQHCs involved, with Sage, and with MITRE to provide ongoing feedback on the REALM</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>University of Rochester</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>500 Joseph C Wilson Blvd</AddressLine1Txt>
          <CityNm>Rochester</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>14627</ZIPCd>
        </USAddress>
        <RecipientEIN>160743209</RecipientEIN>
        <CashGrantAmt>7667</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>Provide consultation on interpretation and guidance on mPower 1.0 analysis and design and scientific strategy for mPower 2.0 data collection.</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>New York University</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>One Park Ave</AddressLine1Txt>
          <AddressLine2Txt>6th Floor</AddressLine2Txt>
          <CityNm>New York</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10016</ZIPCd>
        </USAddress>
        <RecipientEIN>135562308</RecipientEIN>
        <CashGrantAmt>5677</CashGrantAmt>
        <NonCashAssistanceAmt>0</NonCashAssistanceAmt>
        <PurposeOfGrantTxt>Data generation and analysis for the Proteogenomics Computational Challenge</PurposeOfGrantTxt>
      </RecipientTable>
      <Total501c3OrgCnt>17</Total501c3OrgCnt>
      <TotalOtherOrgCnt>0</TotalOtherOrgCnt>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule I, Part I, Line 2</FormAndLineReferenceDesc>
        <ExplanationTxt>In 2018, Sage Bionetworks issued grants, contributions, and prizes. Contributions were given in support of an awarded institution's project and prizes were awarded to research challenge winners. Monitoring the use of grant funds: In some cases, grants received by Sage Bionetworks are passed on to sub-recipients through a sub-award agreement. The Grant Manager is responsible for initiating the sub-award after obtaining budget approval from the PI and Operations Director. In issuing a sub-award, the Grant Manager is responsible for: obtaining verification of the sub-awardee's facilities and administrative rates and Single Audit Reports; reviewing the prime award special terms and conditions to determine whether they are applicable to the sub-award; and determining whether the sub-awardee meets all of the other administrative and regulatory requirements of the prime award. Once the sub-award has been issued, the Grant Manager is responsible for monitoring sub-award activity, including compliance with all reporting requirements. The Grant Manager is also responsible for forwarding the fully executed sub-award documents to the Accounting Manager to ensure proper billing. Payments are made only after the sub-award agreement has been fully executed by both parties.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleI>
    <IRS990ScheduleJ documentId="R000007" softwareId="18007995" softwareVersionNum="v1.00">
      <FirstClassOrCharterTravelInd>X</FirstClassOrCharterTravelInd>
      <WrittenPolicyRefTAndEExpnssInd>1</WrittenPolicyRefTAndEExpnssInd>
      <SubstantiationRequiredInd>1</SubstantiationRequiredInd>
      <CompensationCommitteeInd>X</CompensationCommitteeInd>
      <SeverancePaymentInd>0</SeverancePaymentInd>
      <SupplementalNonqualRtrPlanInd>0</SupplementalNonqualRtrPlanInd>
      <EquityBasedCompArrngmInd>0</EquityBasedCompArrngmInd>
      <CompBasedOnRevenueOfFlngOrgInd>0</CompBasedOnRevenueOfFlngOrgInd>
      <CompBsdOnRevRelatedOrgsInd>0</CompBsdOnRevRelatedOrgsInd>
      <CompBsdNetEarnsFlngOrgInd>0</CompBsdNetEarnsFlngOrgInd>
      <CompBsdNetEarnsRltdOrgsInd>0</CompBsdNetEarnsRltdOrgsInd>
      <AnyNonFixedPaymentsInd>0</AnyNonFixedPaymentsInd>
      <InitialContractExceptionInd>0</InitialContractExceptionInd>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>Lara Mangravite</PersonNm>
        <TitleTxt>President</TitleTxt>
        <BaseCompensationFilingOrgAmt>245496</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>0</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>0</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>36644</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>282140</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>Diane Gary</PersonNm>
        <TitleTxt>Secretary</TitleTxt>
        <BaseCompensationFilingOrgAmt>166446</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>0</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>0</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>30837</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>197283</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>John Wilbanks</PersonNm>
        <TitleTxt>Chief Commons Officer</TitleTxt>
        <BaseCompensationFilingOrgAmt>231848</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>0</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>0</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>21981</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>253829</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>Mike Kellen</PersonNm>
        <TitleTxt>Chief Technology Officer</TitleTxt>
        <BaseCompensationFilingOrgAmt>210759</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>0</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>0</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>23947</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>234706</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>Justin Guinney</PersonNm>
        <TitleTxt>Vice President, Computational Oncology</TitleTxt>
        <BaseCompensationFilingOrgAmt>195821</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>0</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>0</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>36057</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>231878</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>Larsson Omberg</PersonNm>
        <TitleTxt>Vice President, Systems Biology</TitleTxt>
        <BaseCompensationFilingOrgAmt>166446</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>0</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>0</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>30832</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>197278</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>Bruce Hoff</PersonNm>
        <TitleTxt>Director, Synapse Team</TitleTxt>
        <BaseCompensationFilingOrgAmt>166334</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>0</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>0</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>39614</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>205948</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>Erin Mounts</PersonNm>
        <TitleTxt>Principle SW Engineer</TitleTxt>
        <BaseCompensationFilingOrgAmt>161735</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>0</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>0</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>30504</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>192239</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>Dwayne Jeng</PersonNm>
        <TitleTxt>Principal SW Engineer</TitleTxt>
        <BaseCompensationFilingOrgAmt>156897</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>0</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>0</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>19987</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>176884</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>Alx Dark</PersonNm>
        <TitleTxt>Principle Software Engineer</TitleTxt>
        <BaseCompensationFilingOrgAmt>156811</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>0</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>0</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>11529</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>168340</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>John Woodburn</PersonNm>
        <TitleTxt>Director, Design</TitleTxt>
        <BaseCompensationFilingOrgAmt>154830</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>0</BonusFilingOrganizationAmount>
        <BonusRelatedOrganizationsAmt>0</BonusRelatedOrganizationsAmt>
        <OtherCompensationFilingOrgAmt>0</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>0</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>19835</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>174665</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule J, Part I, Line 1a</FormAndLineReferenceDesc>
        <ExplanationTxt>All travel conducted per the company travel policy.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule J, Part I, Line 3</FormAndLineReferenceDesc>
        <ExplanationTxt>Setting executive compensation is the responsibility of the Board of Directors Compensation Committee.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleJ>
    <IRS990ScheduleM documentId="R000008" softwareId="18007995" softwareVersionNum="v1.00">
      <Form8283ReceivedCnt>0</Form8283ReceivedCnt>
      <AnyPropertyThatMustBeHeldInd>0</AnyPropertyThatMustBeHeldInd>
      <ReviewProcessUnusualNCGiftsInd>0</ReviewProcessUnusualNCGiftsInd>
      <ThirdPartiesUsedInd>0</ThirdPartiesUsedInd>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Schedule M, Part I, Line 33</FormAndLineReferenceDesc>
        <ExplanationTxt>Received In-Kind legal services.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleM>
    <IRS990ScheduleO documentId="R000009" softwareId="18007995" softwareVersionNum="v1.00">
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Form 990, Part VI, Section B, Line 11b</FormAndLineReferenceDesc>
        <ExplanationTxt>The 990 is reviewed by the company's Vice President of Operations and President prior to filing.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Form 990, Part VI, Section B, Line 12c</FormAndLineReferenceDesc>
        <ExplanationTxt>Sage Bionetworks has a Financial Conflict of Interest Policy (FCOI) that complies with the National Institutes of Health-specific requirements promoting objectivity in research, 42 CFR Part 50 subpart F. On an annual basis, Sage Bionetworks Officers, Directors, and members of committees of Board of Directors authorized to act on behalf of the board, and employees designated by the President of Sage Bionetworks, including any employees serving as an investigator on a federal/Public Health Services award, must review and update the Sage Bionetworks Annual Conflict of Interest Questionnaire. New employees serving as investigators are required to complete a FCOI form within 30 days of their start date. In addition, all investigators must submit an ad hoc disclosure of a Significant Financial Interest they acquire or discover during the course of the year within 30 days of discovering or acquiring the Significant Financial Interest. Forms are reviewed and any potential conflicts are referred to the President and outside counsel.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Form 990, Part VI, Section B, Line 15</FormAndLineReferenceDesc>
        <ExplanationTxt>Executive compensation was set by the Board of Directors Compensation Committee.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Form 990, Part VI, Section C, Line 19</FormAndLineReferenceDesc>
        <ExplanationTxt>The organization's financials are contained within its 990 returns. These returns are available to the public through organizations such as Guidestar, dedicated to publicizing information about nonprofit organizations. The organization's governing documents and conflict of interest policies are available upon request.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>Form 990, Part IX, Line 11g</FormAndLineReferenceDesc>
        <ExplanationTxt>Scientific Reseach Expenses $1,109,936; Assembly Expenses $179,475; Platform/Scientific Computing Expenses $847,697; Professional Services Expenses $235,191.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleO>
    <ReasonableCauseExplanation documentId="R000010" softwareId="18007995" softwareVersionNum="v1.00">
      <ExplanationTxt>CPA Single Audit was not completed until the end of September.</ExplanationTxt>
    </ReasonableCauseExplanation>
  </ReturnData>
</Return>